Medigene Receives Clinical Trial Approval for Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia
Advertisement
Medigene AG announced that the Norwegian Medicines Agency (NoMa) and the relevant Ethic Committee have granted the approval to conduct a phase I/II clinical trial with its dendritic cell (DC) vaccine. Thereby, all regulatory prerequisites for the study start are fulfilled. The trial for the treatment of acute myeloid leukaemia (AML) will enroll patients for which standard therapies failed and will generate further clinical feasibility and safety data for Medigene's personalized DC vaccines. Further information will be published with study start.